Improved humoral immune response of oil adjuvant vaccine by saponin co-adjuvantation against haemorrhagic septicaemia in mice and buffalo calves

Sujeet Kumar; V K Chaturvedi; B Kumar; P Kumar; S R Somarajan; A Kumar; A S Yadav; B Sharma

doi:10.56093/ijans.v82i9.23644

Authors

Sujeet Kumar Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
V K Chaturvedi Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
B Kumar Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
P Kumar Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
S R Somarajan Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
A Kumar Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
A S Yadav Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India
B Sharma Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India

https://doi.org/10.56093/ijans.v82i9.23644

Keywords:

Buffalo, Co-adjuvantation, Haemorrhagic septicaemia, Oil adjuvant vaccine, Pasteurella multocida' Saponin

Abstract

Oil adjuvant vaccine (OAV) formulations, viz. OAV (OAV without saponin) and S-OAV (OAV with 420 µg saponin/ ml) were prepared against haemorrhagic septicaemia using Pasteurella multocida, P52 antigen. Three groups of mice, each group with 40 mice, were inoculated with respective OAV, S-OAV and sterile phosphate buffer saline and monitored the ELISA antibody titer for 45 days. In another experiment, 2 groups of buffalo calves, each group with 3 calves, were vaccinated with OAV and S-OAV and monitored the ELISA antibody titer for 4.5 months. Viscosity of OAV was 222.28 and of S-OAV 215.10 centipoise. The anti-P. multocida specific serum ELISA antibody titers were significantly higher in S-OAV on 14th days post vaccination compared to OAV and control and remained consistently higher during the experiment. Fluorescent activated cell sorter study revealed that CD4 T cells were significantly higher in S-OAV group as compared to OAV and control, while CD8 T cells was 28.83% higher than control. All vaccinated groups were 100% protected after direct intraperitoneal challenge with 100 LD50 of live P. multocida, serotype B, strain P52 on 45th DPV. However, after challenge with 1000 LD50 the S-OAV group had 80% protection as compared to 60% protection by OAV. Trial on buffalo calves further confirmed the finding of mice model as higher ELISA antibody titers were observed by S-OAV group as compared to OAV throughout the experiment period since seventh DPV onwards. Thus, saponin co- adjuvantation of OAV increased the CD4, CD8 T cells population, improved the humoral immune response and protection.

Downloads

Download data is not yet available.

References

Anonymous. 1994. Drugs and cosmetics acts and rules (VI amendment), Government of India.

Bain R V S, Alwis M C I, Carter G R, Gupta B K and Fao R. 1982. Haemorrhagic septicaemia. Animal Production and Health Paper (FAO) No. 33, Rome.

Briggs D J and Skeeles J K. 1984. An enzyme-linked immunosorbent assay for detecting antibodies to Pasteurella multocida in chickens. Avian Diseases VOL?: 208–15.

Chandrasekaran S, Kennett L, Yeap P C, Muniandy N, Rani B and Mukkur T K S. 1994. Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines. Veterinary microbiology 41: 213–19.

Chang J C C, Diveley J P, Savary J R and Jensen F C. 1998. Adjuvant activity of incomplete Freund’s adjuvant. Advanced Drug Delivery Reviews 32: 173–86.

Dawkins H J S, Johnson R B, Spencer T L and Adler B. 1990. Pasteurella multocida infections in mice with reference to haemorrhagic septicaemia in cattle and buffalo. Immunology and Cell Biology 68: 57–61.

Dutta J, Rathore B S, Mullick S G, Singh R and Sharma G C. 1990. Epidemiological studies on occurrence of haemorrhagic septicaemia in India. Indian Veterinary Journal 67: 893–99.

Freund J. 1951. The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. American Journal of Clinical Pathology 21: 645–45.

Harrison G B L, Shakes T R, Robinson C M, Lawrence S B, Heath D D, Dempster R P, Lightowlers M W and Rickard M D. 1999. Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants. Veterinary immunology and immunopathology 70: 161–72.

Kumar A, Srivastava N C and Singh V P. 2009. Immunogenicity of Mycoplasma agalactiae saponin vaccine in mice. Indian Journal of Comparative Microbiology, Immunology and Infectious Diseases 30: 61–62.

Kumar S, Chaturvedi V K, Kumar B and Kumar P. 2011. Immune response and viscosity of haemorrhagic septicaemia oil adjuvant vaccine at different water-oil proportion. Indian Journal of Animal Sciences 81: 1000–04.

Martinez-Fernandez A R, Nogal-Ruiz J J, Loprez-Aban J, Ramajo V, Oleaga A, Manga-Gonzalez Y, Hillyer G V and Muro A. 2004. Vaccination of mice and sheep with Fh12 FABP from Fasciola hepatica using the new adjuvant/immunomodulator system ADAD. Veterinary Parasitology 126: 287–98.

Misra R P. 1985. Manual of Production of Haemorrhagic Septicaemia Vaccine. FAO, UNDP: 24.

Mutwiri G, Gerdts V, Van Drunen L H, Auray G, Eng N, Garlapati S, Babiuk L A and Potter A, 2011. Combination adjuvants: the next generation of adjuvants? Expert Review of Vaccines 10: 95–107.

OIE. 2008. Haemorrhagic septicaemia chapter 2.4.12. OIE Terrestrial Manual. 739–51.

Okerman L and Devriese L A. 1987. Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit Pasteurella multocida vaccine. Vaccine 5: 315–18.

Reed L J and Muench H. 1938. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 27: 493–93.

Smitsaart E, Esponoza A M, Sanguinetti R, Filippi J, Ham A and Bellinzoni R. 2004. Addition of saponin to double oil emulsion FMD vaccines enhances specific antibody responses in cattle and pigs. Report on the European Commission for the control of foot-and-mouth disease. Session of the Research Group of the Technical Standing Committee, Food and Agriculture Organization of the United Nations, Chania, Greece, 11–15 October 2004, 344–51.

Song X and Hu S. 2009. Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine 27: 4883–90.

Sun H X, Xie Y and Ye Y P. 2009. Advances in saponin-based adjuvants. Vaccine 27: 1787–96.

Verma R and Jaiswal T N. 1997. Protection, humoral and cell mediated immune responses in calves immunized with multiple emulsion haemorrhagic septicaemia vaccine. Vaccine 15: 1254– 60.

Verma R and Jaiswal T N. 1998. Haemorrhagic septicaemia vaccines. Vaccine 16: 1184–92.

Waite D C, Jacobson E W, Ennis F A., Edelman R, White B, Kammer R, Anderson C and Kensil C R. 2001. Three double- blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19: 3957–67.

Xiao C, Rajput Z I and Hu S. 2007. Improvement of a commercial foot-and-mouth disease vaccine by supplement of Quil A. Vaccine 25: 4795–00.

Yang Y W, Wei A C and Shen S S. 2005. The immunogenicity- enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate–a revisit of the role of the hydrophile-lipophile balance (HLB) value. Vaccine 23: 2665–75.